Calypte(765254) scheint aufzuerstehen!

Study nurses responsible for the collection of samples described OMT (oral fluid test) collection as "easy to do", and preferred the non-invasive oral fluid collection method to the blood collection currently in use. Laboratory personnel found the test procedure simple to perform and results easy to interpret. "This assay may be a suitable alternative for VCT practices," was the poster's conclusion.

Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "We have long known the accuracy of the Aware(TM) HIV-1/2 oral fluid rapid test. The usage studies that are now being reported are focusing on the social aspects of such a test and we are pleased that there is strong sentiment for adopting oral fluid testing. While changing long-established blood collection practice to the OMT method is a process, we believe we are gaining momentum in making oral fluid an acceptable alternative to blood testing. The recent approval of our oral fluid test in India and the subsequent interest we are seeing from the government, military and private sectors is very encouraging in this regard."

Johannes Viljoen, MBChB, FC Path (SA) Viro, at the College of Health Sciences of the University of KwaZulu-Natal, Durban, South Africa and principal investigator presenting this poster noted, "We specialize with individuals living in rural settings of South Africa. In South Africa there are ongoing public health and media campaigns to increase public awareness and uptake of HIV testing in an attempt to curb the spread of the epidemic. We anticipate that offering a non-invasive rapid test may quite possibly result in an enhanced uptake of testing, mostly as a result of it being more acceptable and painless, even more so for children. In our study, the technique was clearly preferred over finger-sticks by the health care providers."

Dr. Pravi Moodley, Acting Head of the Department of Virology at the University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa and a co-author of the poster commented, "The sampling of oral fluid for HIV antibody rapid testing in resource constrained settings has advantages over the conventional finger-prick blood which is currently used for HIV antibody rapid testing. The obtaining of an oral fluid sample is much simpler since a community health worker requiring minimal training will be able to obtain the sample. It is also much safer since no sharps and sharps containers are necessary, obviating the need for intensive health and safety training which may unnecessarily consume financial and human resources in already resource constrained settings."

Further, our field evaluation of Calypte's Aware(TM) HIV-1/2 OMT Rapid Test showed excellent correlation with blood samples," concluded Dr. Moodley.

Calypte to Present at the First Annual CapStone Investments Small-Cap Institutional Investor Conference

LAKE OSWEGO, Ore., July 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --

Calypte Biomedical Corporation (OTCBB: CBMC), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV) announced today that Roger I. Gale, Chairman and Chief Executive Officer and Richard D. Brounstein, Executive Vice President, will speak to the investment community at CapStone Investments' First Annual Small-Cap Investor Conference in Milwaukee, Wisconsin. The conference will be archived for on-demand webcasting after the conference has concluded.

Mr. Gale and Mr. Brounstein will provide an update regarding the Company's recent activities at CapStone Investments' First Annual Small-Cap Investor Conference in Milwaukee, Wisconsin at approximately 2:30pm CDT on Tuesday, July 17, 2007. The presentation will be publicly available at www.capstoneinvestments.com/page.asp?itemid=62 after the conference concludes on Tuesday

Kann mir gut vorstellen, dass nun wieder Vertrauen darin entsteht, dass es doch erhebliche Umsätze mit dem HIV-Test geben kann.
Bin auch mal gespannt, wie versucht werden wird, zu pushen. Das macht die Aktie nur volatil und hilft evtl. den daytradern, nicht aber denen, die (wieder) Vertrauen in die Aktie fassen wollen. Lasst es doch bitte sein. Die Kurse werden ohnehin nur in den USA gemacht!
Grüße
Didi (zur Zeit im Land der Dicken)

Besser kann mann eine Präsentation nicht machen, Klasse Mr.Gale  

Leute schaut euch dies an      

hosted.mediasite.com/hosted4/Catalog/...4f8b-a522-307af3f58415

Jetzt gits nur noch eins....... nach oben    

unten links auf
CBMC—Calypte Biomedical Corp. klicken und genießen          

hosted.mediasite.com/hosted4/Catalog/...4f8b-a522-307af3f58415

besser kann man echt keine Präsentation gestalten  

habe mit caly jede menge kohle gemacht!!

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

GEHT LOS

na, da scheint sich unsere Geduld ja auszuzahlen.
Weißt Du eigentlich, welche Stoffe im Speichel gebildet werden, die jetzt den (indirekten?) Nachweis auf Aids ergeben?  

die Antikoerperbildung gegen ein Antigen (auch Agens genannt; hier das Retrovirus HIV) ist ein BESTANDTEIL der Immunreaktion des menschlichen Koerpers. Bei aktiven Impfungen z.B. wird ein Antigen (stark abgeschwaecht) in den Koerper injiziert und er bildet Antikoerper dagegen.

Chua Thiam Eng, a general practitioner at Cambridge Clinic, said, "If we think about which situation we are better off with -- continue not testing at all, or testing anonymously with the hope that these people take responsibility for the results -- it is better to test." Lionel Lee, executive director of Action for AIDS, said that any testing program must have support mechanisms, such as counseling, in place. Lee added that AFA's policy is to "counsel those who test positive to go into the system (by informing the Communicable Disease Center), as this gives them better access to treatment and support" (Today, 7/27).

Reprinted with kind permission from www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
--------------------------------------------------

Article URL: www.medicalnewstoday.com/articles/78252.php

Main News Category: HIV / AIDS


--------------------------------------------------

Prior to consulting to the medical device industry, Mr. Clark was the co-founder, Chairman and CEO of MagneVu, a private medical device company, where he guided the company through its start up period and the FDA approval process, and established a product that later would be marketed by GE Medical Systems. Prior to MagneVu, Mr. Clark held several CEO and senior management positions within the medical device industry, including a 12-year career with Johnson & Johnson's Technicare division, where he was U.S. Corporate Vice President of Customer Relations.

While at Johnson & Johnson Mr. Clark's extensive International experience included overseas sales and operational assignments with responsibility for Pacific Rim countries including Japan, Korea, Indonesia, Malaysia, Taiwan, Hong Kong, Singapore and the Philippines, as well as countries in Europe, Eastern Europe, the Middle East and Africa. He began his career as a sales representative for Becton, Dickenson & Co. Mr. Clark holds a Bachelor of Science and a Master of Arts degree in communications from Eastern New Mexico University.

Mr. Clark commented, "I expect to be able to make an immediate impact by establishing a sales distribution organization. With larger company and extensive international hands-on experience, as well as several years as CEO of companies similar to Calypte, I look forward to working with Roger and the management team at this point in the Company's evolution. Calypte has proven products at the beginning of their growth cycle and an anticipated pipeline of complementary products to follow. I am pleased to join Calypte at this time and help accelerate its growth curve."

About Calypte Biomedical:

Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the AwareTM HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.

vielleicht würde es ja ganz einfach helfen ein paar von den Dingern auch
zu verkaufen!
Dann klappts vielleicht auch mal mit "...the next phase of our Company's growth."